Clinical Trial Search

Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment — 5.6…

Primary: Number of Participants With Return to Baseline Respiratory Function. — 11; 9 Participants

Primary: Changes in Evoked Functional Brain Activity Pre/Post Short iTBS Stimulation Before and After the 3-Day TMS Intervention Regimen — -0.2684097; -0.1897918; -0.2640429…

Primary: Change in Depression Score for Caregiver as Measured by CES-D — 9; 10; 9; 8 units on a scale

Primary: Change in Foot Strike Pattern From Baseline — 79; 83; 68; 73 percentage of non-rearfoot strike patter

Primary: Comparison Between Contrast Fractional Flow Reserves (cFFR) and Adenosine Fractional Flow Reserves (aFFR) — 0.8922 proportion of lesions with agreement

Primary: Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 6; 6; 3 participants

Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)

Primary: Safety (Adverse Event Rate) — 20 adverse events per participant

Primary: Change in Roland Morris Disability Questionnaire Score — -4.38; -0.12; 0.18; -3.64 units on a scale — p=.001

Primary: Phase 1b: Number of Participants With Adverse Events as Per Severity — 0; 0; 2; 26 Participants

Primary: Pain Levels — 2.4; 3 units on a scale

Primary: Clinical Response — 5; 2; 1 Participants

Primary: Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated Serine312-insulin Receptor Substrate-1 (pS312-IRS-1) — 79.01; 443.72; -337.70; -608.92 pg/mL

Primary: Intervention Efficacy for High Dose : Global Cognitive Function as Calculated From the Change From Baseline to Month 6 — 0.40; 0.07; 1.46; -0.44 units on a scale — p=0.87